Personalized chemo before breast cancer surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have HER2-positive breast cancer that hasn't spread beyond the breast or nearby lymph nodes (stages T1c to T3 and N0 to N2).
- Your tumor must show a HER2-enriched pattern on a special gene test (MammaPrint/BluePrint).
- You cannot have received any treatment yet for this breast cancer.
- Your heart function (left ventricle pumping strength) must be at least 50%.
- Your organs (kidneys, liver, bone marrow) must work well enough, as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
This trial tests whether a customized treatment plan given before surgery can improve outcomes for women with early-stage HR-positive, HER2-positive breast cancer. The goal is to shrink the tumor and make surgery more effective.
This trial tests a combination of targeted drugs (Initumab and Pyrrotinib) plus chemotherapy before surgery for HER2-positive breast cancer. It compares different treatment lengths to see which is more effective and safe.
This trial tests a personalized treatment plan for HER2-positive breast cancer before surgery. The treatment is adjusted based on how your cancer responds, aiming to give you the best possible outcome.
This trial tests a new combination of two chemotherapy drugs (Utidelone and Cisplatin) given before surgery for breast cancer. It is for people with early-stage breast cancer that has not spread to other parts of the body, and aims to shrink the tumor to make surgery more effective.
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.